Skip to content

Earnings call

Narayana Hrudayalaya Q1 FY26 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Management expects the new business to reach breakeven to slightly positive by the end of the year or 1st Quarter next year, while its margin profile will differ from the services business. The company has close to 1,800 beds in ICUs. The Arya scheme had about 6,000 lives at the moment of the call. The company is looking at a maximum leverage ratio at the consolidated level of around 2.5-3, and the same for the respective entities.

The numbers management gave

Results

  • The Arya scheme had about 6,000 lives at the moment of the call.
    Show source
    We've got about 6,000 lives at the moment, and we are now seeing acceleration in that pace as well.
  • The company domestic revenue grew by 12% in Q1 FY26, contributing to ARPP as domestic revenue substituted for Bangladesh revenue, which had almost a 50% drop from the same quarter last year and lower realization.
    Show source
    So, that having been substituted by domestic revenue, domestic revenue has grown by 12% this quarter.
  • The company had almost a percentage improvement in payor mix from last year to this year, which helped ARPP.
    Show source
    As you can see, from last year to this year we have had almost a percentage improvement in the payor mix.
  • Increase in costs included a big chunk from minimum-wage revisions across states, affecting housekeeping and security costs, and increased hospital equipment R&M and costs relating to robotic investments.
    Show source
    A big chunk is because of the minimum wages’ revision across states.
  • CSR commitments increased because its three-year average profit rose after the effect of the COVID year left the base.
    Show source
    So, therefore, our three-year average profit has gone up, and therefore, our CSR commitments have also gone up.

Money and capital

  • The company is looking at a maximum leverage ratio at the consolidated level of around 2.5-3, and the same for the respective entities.
    Show source
    For us, we are looking at the maximum leverage ratio at the consol level of around 2.5-3 and same for the respective entities as well.
Show 4 more statements

Money and capital

  • The company has announced projects of about INR 3,000 crores; it will borrow roughly 80% of that and repay over a 10-to-15-year time period.
    Show source
    Roughly, 80% of that we will borrow.
  • The company has announced almost INR 3,000 crores of incremental Capex.
    Show source
    So, we have announced almost INR 3,000 crores of incremental Capex.
  • The company expects INR 2,400 crores of debt to come onto the books in the next three years, plus regular capex of around INR 300-350 crores every year; gross debt will increase by around INR 800 to 1000 crores every year, minus repayments on existing loans.
    Show source
    So, there'll be addition of around INR 800 to 1000 crores of gross debt every year , minus the repayment on the existing loans.
  • The company Limited is projecting in the right trajectory, with absolute cash burn in the current quarter lower than in the previous quarter, and is sticking to its indicated overall cash burn number for both businesses put together.
    Show source
    And as you can see, the absolute cash burn in the business in the current quarter is lower than what it was in the previous quarter.

What it expects ahead

What management expects

  • Management expects the new business to reach breakeven to slightly positive by the end of the year or 1st Quarter next year, while its margin profile will differ from the services business.
    Show source
    Longer term, we expect this to be a breakeven to plus or minus, slightly positive, hopefully by the end of the year or 1st Quarter next year.
  • The company Limited aims to move oncology towards 20-25% as a percentage of revenue and expects good year-on-year growth, following the trajectory it has observed and worked towards with the clinical team and its investments.
    Show source
    And the aim is to get towards that number which you've mentioned, and we will be seeing a good healthy growth year-on-year on that.
  • The company Limited is working to bring ALOS closer to 4 and hopes it will continue to come down in the future; quarterly fluctuations may occur because of seasonality, while the long-term trend is towards lower ALOS.
    Show source
    Dr. Emmanuel Rupert: We are working towards this, I mean, we want to bring it down to closer towards 4 and we are working towards this.

What it is building and selling

Projects and capacity

  • The company has close to 1,800 beds in ICUs.
    Show source
    The Bangalore Hospital is also close to 1,800 beds.
  • The building shell has come up, and interiors are underway while medical equipment is being ordered; the project will take about a year. Replaced by a later filing.
    Show source
    The building shell has already come up, we are doing on the interiors and ordering the medical equipment.

Segments

  • Over the quarter, the Arya scheme started in Kolkata, Shimoga and Raipur.
    Show source
    6 Over the quarter, we started in Kolkata, Shimoga and Raipur.
  • The company Limited developed and took to market a group omnibus product for non-employer-employee plans, opening potential opportunities to partner with external parties that have pools of customers.
    Show source
    We've also developed and taken to market a group omnibus product for non-employer-employee plans, which is something we're actually quite excited about, because it opens up new opportunities for us to partner with external parties, potentially, that have got pools of customers.
  • The company Limited rolled out NAMAH, its nurse application, as well as inpatient digital modules including the medication card, and hopes these will stabilize by October.
    Show source
    It's getting stabilized, and we hope that it will get stabilized somewhere by October.
  • Ayushman Bharat accounts for roughly less than half of Narayana Hrudayalaya Ltd.'s scheme patient mix.
    Show source
    But, yes, roughly less than half, we can say.
Show 1 more statement

Segments

  • The company Limited launched Aditi Plus, an upgraded version of its first plan, Aditi, for the Kolkata market. Replaced by a later filing.

Everything else said on the call

What management stressed

  • The company Limited is working with MED HA, its analytical division, on operational improvements intended to speed up discharges, streamline clinical and operational documentation, and enable processes to happen more quickly.
    Show source
    All these things will speed up the discharges and other things, because we are working along with our MED HA, which is the analytical division, to work towards multiple improvements in the operational efficiencies, so that we'll be able to streamline the processes and make documentation, both clinical and operational documentation, much more streamlined and enable things to happen in a much quicker way.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

This transcript does not separate questions and answers, so they are not listed here.

Questions about this call

When was the Narayana Hrudayalaya Q1 FY26 earnings call transcript filed?
Narayana Hrudayalaya filed the transcript with the exchange on 11 Aug 2025. This page is built from that transcript.
What does this page list?
21 statements from the transcript across 6 topics, 10 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
No. This transcript does not separate the questions from the answers, so they are not listed. The statements by topic still cover what management said.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Narayana Hrudayalaya Q1 FY26 concall: what the company said · DalalOS